Difluprednate
From Wikipedia, the free encyclopedia
|
Difluprednate
|
|
| Systematic (IUPAC) name | |
| [(6S,8S,9R,10S,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydr
oxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenant hren-17-yl] butanoate |
|
| Identifiers | |
| CAS number | |
| ATC code | D07 |
| PubChem | |
| Chemical data | |
| Formula | C27H34F2O7 |
| Mol. mass | 508.551 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | topical dermatologic |
Difluprednate is a corticosteroid, a derivative of prednisolone obtained by fluorination at the 6- and 9-positions, followed by esterification of the 17 and 21-hydroxyl groups with butyric acid and acetic acid, respectively (see figure). Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate.

